These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 16330674)

  • 1. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
    O'Connor OA; Heaney ML; Schwartz L; Richardson S; Willim R; MacGregor-Cortelli B; Curly T; Moskowitz C; Portlock C; Horwitz S; Zelenetz AD; Frankel S; Richon V; Marks P; Kelly WK
    J Clin Oncol; 2006 Jan; 24(1):166-73. PubMed ID: 16330674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
    Giles F; Fischer T; Cortes J; Garcia-Manero G; Beck J; Ravandi F; Masson E; Rae P; Laird G; Sharma S; Kantarjian H; Dugan M; Albitar M; Bhalla K
    Clin Cancer Res; 2006 Aug; 12(15):4628-35. PubMed ID: 16899611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
    Kelly WK; O'Connor OA; Krug LM; Chiao JH; Heaney M; Curley T; MacGregore-Cortelli B; Tong W; Secrist JP; Schwartz L; Richardson S; Chu E; Olgac S; Marks PA; Scher H; Richon VM
    J Clin Oncol; 2005 Jun; 23(17):3923-31. PubMed ID: 15897550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    O'Connor OA; Wright J; Moskowitz C; Muzzy J; MacGregor-Cortelli B; Stubblefield M; Straus D; Portlock C; Hamlin P; Choi E; Dumetrescu O; Esseltine D; Trehu E; Adams J; Schenkein D; Zelenetz AD
    J Clin Oncol; 2005 Feb; 23(4):676-84. PubMed ID: 15613699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
    Rizzieri DA; Feldman E; Dipersio JF; Gabrail N; Stock W; Strair R; Rivera VM; Albitar M; Bedrosian CL; Giles FJ
    Clin Cancer Res; 2008 May; 14(9):2756-62. PubMed ID: 18451242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
    DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
    Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical studies of histone deacetylase inhibitors.
    Prince HM; Bishton MJ; Harrison SJ
    Clin Cancer Res; 2009 Jun; 15(12):3958-69. PubMed ID: 19509172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Modesitt SC; Sill M; Hoffman JS; Bender DP;
    Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
    Kelly WK; Richon VM; O'Connor O; Curley T; MacGregor-Curtelli B; Tong W; Klang M; Schwartz L; Richardson S; Rosa E; Drobnjak M; Cordon-Cordo C; Chiao JH; Rifkind R; Marks PA; Scher H
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3578-88. PubMed ID: 14506144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
    Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.
    Marks PA; Breslow R
    Nat Biotechnol; 2007 Jan; 25(1):84-90. PubMed ID: 17211407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
    J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
    Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
    BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
    Kelly WK; Marks PA
    Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
    Zhao WL; Wang L; Liu YH; Yan JS; Leboeuf C; Liu YY; Wu WL; Janin A; Chen Z; Chen SJ
    Exp Hematol; 2007 Dec; 35(12):1801-11. PubMed ID: 17681667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.
    Cohen LA; Marks PA; Rifkind RA; Amin S; Desai D; Pittman B; Richon VM
    Anticancer Res; 2002; 22(3):1497-504. PubMed ID: 12168829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and development of SAHA as an anticancer agent.
    Marks PA
    Oncogene; 2007 Feb; 26(9):1351-6. PubMed ID: 17322921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P; Bolis S; Brivio F; Fumagalli L
    Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.